Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ZOLADEX LA DEPOT INJECTION 10.8 MG/SYRINGE [SIN09793P]

Active ingredients: GOSERELIN

View product's general information
Last updated on 9 October 2026

Product Info

ZOLADEX LA DEPOT INJECTION 10.8 MG/SYRINGE

[SIN09793P]

Product information

Active Ingredient and Strength

GOSERELIN - 10.8 MG/SYRINGE

Dosage Form

INJECTION

Manufacturer and Country

ASTRAZENECA UK LTD - UNITED KINGDOM

Registration Number

SIN09793P

Licence Holder

ASTRAZENECA SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L02AE03

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

(i) Prostate cancer: ZOLADEX LA 10.8mg is indicated in the management of prostate cancer suitable for hormonal manipulation.

(ii) Endometriosis: ZOLADEX LA 10.8mg is indicated in the management of endometriosis including alleviation of symptoms, such as pain, and reduction in the size and number of endometrial lesions.

(iii) Uterine fibroids: ZOLADEX LA 10.8mg is indicated in the management of fibroids including shrinkage of lesions, improvement in the patient’s haematological status and reduction of symptoms, such as pain. It can be used as an adjunct to surgery to facilitate the operative technique and reduce operative blood loss.

(iv) Breast cancer: ZOLADEX LA 10.8mg is indicated in the management of estrogen-receptor-positive breast cancer in premenopausal women.

Dosing

4.2 Posology and method of administration

Caution should be taken while inserting ZOLADEX LA 10.8mg into the anterior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches.

Use extra care when administering ZOLADEX LA 10.8mg to patients with a low body mass index and/or who are receiving full anticoagulation medication (see Section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

For correct administration of ZOLADEX LA 10.8mg, see instructions on instruction card (see Section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Adult Men: One 10.8mg depot of ZOLADEX LA 10.8mg injected subcutaneously into the anterior abdominal wall, every 3 months (see Section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Adult Women: One depot of ZOLADEX LA 10.8mg injected subcutaneously into the anterior abdominal wall, every 12 weeks.

Elderly: No dosage adjustment is necessary in the elderly.

Renal Impairment: No dosage adjustment is necessary for patients with renal impairment.

Hepatic Impairment: No dosage adjustment is necessary for patients with hepatic impairment.

Children: Not indicated for use in children.

Contraindications

4.3 Contraindications

Known hypersensitivity to the active substance, to other LHRH analogues, or to any excipients of this product.

Pregnancy and lactation (see Section 4.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).